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K+ channelsPotassium (K+) channels have been implicated in depressive disorders and in the mechanism of action of
antidepressants. Considering that several studies have indicated that folic acid plays an important role in
the pathophysiology of depression, the present study investigated the involvement of potassium channels
in the antidepressant-like effect of this vitamin. For this aim, the effect of the combined administration of
different types of K+ channel blockers and folic acid in the forced swimming test (FST) was investigated.
Treatment of mice by intracerebroventricular (i.c.v.) route with subactive doses of glibenclamide (an
ATP-sensitive K+ channels blocker, 0.5 pg/site), charybdotoxin (a large- and intermediate-conductance
calcium-activated K+ channel blocker, 25 pg/site) or apamin (a small-conductance calcium-activated K+
channel blocker, 10 pg/site), augmented the effect of folic acid (10 mg/kg, p.o., subeffective dose) in the
FST. Additionally, the administration of folic acid and the K+ channel blockers, alone or in combination, did
not affect locomotion in the open-ﬁeld test. Moreover, the reduction in the immobility time in the FST elicited
by folic acid administered at a higher dose (50 mg/kg, p.o.) was prevented by the pretreatment of mice with
the K+ channel opener cromakalim (10 μg/site, i.c.v.), without affecting locomotor activity. The results of this
study indicate that the antidepressant-like effect of folic acid in the FST may be at least partly due to its
modulatory effects on neuronal excitability, via inhibition of K+ channels.
© 2011 Elsevier Inc. Open access under the Elsevier OA license.1. Introduction
Depression is a chronic, severe and debilitating mental illness that
affects millions of people worldwide. Although the underlying
pathophysiological mechanisms of depression are not completely
established, novel targets have been identiﬁed for the development
of new pharmacological treatments (Lee et al., 2010). There is
increasing evidence that a folic acid status is an important factor
that may contribute to depressive disorders and its treatment
(Coppen and Bolander-Gouaille, 2005; Morris et al., 2008; Sarris
et al., 2009). Folic acid (folate), one of the 13 essential vitamins
which is obtained from dietary sources or supplements, is essential
for the functioning of nervous system, since it displays an important
role in neuroplasticity and maintenance of neuronal integrity
(Fenech, 2010; Kronenberg et al., 2009).
Many important metabolic processes are dependent on folic acid
availability, including the synthesis of norepinephrine, dopamine
and serotonin, which are neurotransmitters implicated in the
pathogenesis and treatment of depression (Fava and Mischoulon,
2009). There are several clinical studies regarding folic acid deﬁciencya, Centro de Ciências Biológicas,
ersitário, Trindade 88040-900,
5 48 3721 9672.
gmail.com (A.L. S. Rodrigues).
vier OA license.associated with a higher incidence of depression. These studies show
that: a) reduced plasma, serum or red blood cell folic acid is common-
ly found in major depressive illnesses (Abou-Saleh and Coppen, 2006;
Sarris et al., 2009); b) a low folic acid status is associated with poorer
response to antidepressant medication; on the other hand, folic acid
supplementation added to antidepressant medication improves its
therapeutic effect (Alpert et al., 2002; Coppen and Bailey, 2000;
Godfrey et al., 1990). Low folic acid status is associated with reduced
serotonergic and/or neurotransmitter function; (c) preclinical studies
from our group have shown that systemic and central administration
of folic acid produces antidepressant-like effect in two predictive
models of antidepressant activity, the forced swimming test (FST)
and tail suspension test (TST) (Brocardo et al., 2008a). The
mechanisms by which folic acid produces antidepressant-like effect
are not fully established, but they were shown to be dependent on
the serotonergic and noradrenergic systems (Brocardo et al., 2008a),
inhibition of N-methyl-D-aspartic acid (NMDA) receptors and nitric
oxide (NO) and cyclic guanosine monophosphate (cGMP) synthesis
(Brocardo et al., 2008b). Additionally, antidepressant-like effect of
folic acid is also mediated by an interaction with the opioid system
(μ1- and δ-opioid receptors) (Brocardo et al., 2009), inhibition of
glycogen synthase kinase-3 (GSK-3β) and activation of peroxisome
proliferator-activated receptor-γ (PPARγ) (Budni et al., 2011b).
NO is an important messenger in the central nervous system. It is
produced from L-arginine by the catalytic action of NO synthase
149J. Budni et al. / Pharmacology, Biochemistry and Behavior 101 (2012) 148–154(NOS). Physiologically, NO actions may be mediated by locally
produced NO and in most instances by the subsequently generated
second messenger molecule guanosine 3′5 cyclic monophosphate.
Studies indicate that different types of K+ channels in several tissues
can be activated by NO per se or through cGMP production (Jeong
et al., 2001; Shin et al., 1997). Additionally, a previous study of our
group demonstrated that the antidepressant-like effect elicited by
the inhibition of several subtypes of K+ channels is dependent on
the inhibition of NO–cGMP synthesis (Kaster et al., 2005). Thus, K+
channels might be one of the physiological targets of NO in the
brain (Jeong et al., 2001) and the inhibition of these channels might
play an important role in the pathophysiology of depression.
Therefore, the aim of this study was to investigate whether the
blockade of K+ channels can contribute to the antidepressant-like
effect of folic acid in the FST in mice.
2. Materials and methods
2.1. Animals
Adult Swiss mice of either sex (homogeneously distributed among
groups), weighing 30–40 g were maintained at 20–22 °C with free
access to water and food, under a 12:12 h light:dark cycle (lights on
at 7:00 am). Male and female mice were maintained in different
cages. All manipulations were carried out between 9:00 am and
4:00 pm, with each animal used only once. All procedures were
performed in accordance with the National Institute of Health Guide
for the Care and Use of Laboratory Animals. The experiments were
performed after approval by the Ethics Committee of the Institution
and all efforts were made to minimize animal suffering and to reduce
the number of animals used in the experiments.
2.2. Drugs and treatment
The following drugs were used: folic acid (Sigma Chemical Co., St.
Louis, U.S.A.), charybdotoxin, cromakalim and glibenclamide (Tocris
Cookson, Ballwin, MO, USA). Cromakalim was dissolved in saline
with 10% Tween 80, whereas all the other drugs were dissolved in
isotonic saline solution (NaCl 0.9%) immediately before use, except
folic acid which was dissolved in distilled water. Appropriate
vehicle-treated groups were also assessed simultaneously. All the
drugs were administered by intracerebroventricular (i.c.v.) route, in
a volume of 5 μl per mouse, except folic acid which was administered
by oral route (p.o.) in a constant volume of 10 ml/kg body weight.
I.c.v. injections were given under light ether anesthesia, directly into
the lateral ventricle as described previously by Budni et al. (2007),
with the bregma ﬁssure as a reference. Vehicle, potassium channel
blockers or potassium channel opener were injected in a volume of
5 μl, given over 30 s, and the cannula remained in place for another
30 s.
To test the hypothesis that the antidepressant-like effect of folic
acid is mediated through the inhibition of K+ channels, animals
were pretreated with a subeffective dose of folic acid (10 mg/kg,
p.o.), and 45 min later they received subeffective doses of glibencla-
mide (an ATP-sensitive K+ channel blocker, 0.5 pg/site), charybdo-
toxin (a large- and intermediate-conductance calcium-activated K+
channel blocker, 25 pg/site) or apamin (a small-conductance
calcium-activated K+ channel blocker, 10 pg/site) before being tested
in the FST.
In order to rule out any psychostimulant effect of the interaction
of K+ channel blockers and folic acid, mice were pretreated by oral
route with folic acid 45 min before the administration by i.c.v. route
of glibenclamide (0.5 pg/site), charybdotoxin (25 pg/site) or apamin
(10 pg/site). The open-ﬁeld test was carried out 15 min later.
In another set of experiments, mice were pretreated with folic acid
(50 mg/kg, p.o.), 45 min before the administration of cromakalim(a K+ channel opener, 10 μg/site, i.c.v.). FST or the open-ﬁeld test
was carried out 15 min later.
The doses of folic acid were chosen based on previous studies from
our group (Brocardo et al., 2008a, 2008b, 2009; Budni et al., 2011b).
The doses of glibenclamide, charybdotoxin, apamin and cromakalim
were chosen on the basis of literature and are previously reported not to
increase locomotor activity (Budni et al., 2007; Galeotti et al., 1999;
Kaster et al., 2005, 2007).
2.3. Forced swimming test (FST)
Brieﬂy, mice were individually forced to swim in an open
cylindrical container (diameter 10 cm, height 25 cm), containing
19 cm of water (depth) at 25±1 °C; the total duration of immobility
was measured during 6-min period as described previously (Brocardo
et al., 2008a; Budni et al., 2007; Kaster et al., 2005). Each mouse was
judged to be immobile when it ceased struggling and remained
ﬂoating motionless in the water, making only those movements
necessary to keep its head above water. A decrease in the duration
of immobility is indicative of an antidepressant-like effect (Porsolt
et al., 1977).
2.4. Open-ﬁeld test
To assess the possible effects of folic acid on locomotor activity,
mice were evaluated in the open-ﬁeld paradigm as previously
described (Budni et al., 2007; Rodrigues et al., 1996). Animals were
individually placed in a wooden box (40×60×50 cm) with the ﬂoor
divided into 12 rectangles. The number of squares crossed with all
paws (crossing) was counted in a 6 min session. The apparatus
were cleaned with a solution of 10% ethanol between tests in order
to hide animal clues.
2.5. Statistical analysis
All experimental results are given as the mean±SEM. Compari-
sons between experimental and control groups were performed by
two-way ANOVA (interaction of folic acid with the pharmacological
agents) followed by Newman–Keuls test when appropriate. A value
of pb0.05 was considered to be signiﬁcant.
3. Results
3.1. Effects of combined administration of subeffective doses of the K+
channel blockers and folic acid in the FST
The results presented in Fig. 1A show the synergistic
antidepressant-like effect of glibenclamide (an ATP-sensitive K+
channel blocker, 0.5 pg/site, i.c.v.) combined with a subeffective dose
of folic acid (10 mg/kg, p.o.) in the FST. The two-way ANOVA revealed
a signiﬁcant effect of glibenclamide treatment [F1,28=12.78, pb0.01]
and pretreatment×treatment interaction [F1,28=16.30, pb0.01], but
not of folic acid pretreatment [F1,28=2.49, p=0.12].
Fig. 1B shows that apamin (a small-conductance calcium-
activated K+ channel blocker, 10 pg/site, i.c.v.) in combination with
a subeffective dose of folic acid reduced the immobility time in the
FST when compared with either drug alone. The two-way ANOVA
revealed a signiﬁcant effect of apamin treatment [F1,28=14.69,
pb0.01] and pretreatment×treatment interaction [F1,28=11.28,
pb0.01], but not of folic acid pretreatment [F1,28=2.67, p=0.11].
As presented in Fig. 1C, the administration of charybdotoxin (a
large- and intermediate-conductance calcium-activated K+ channel
blocker, 25 pg/site, i.c.v.) in combination with subeffective dose of
folic acid also produced an antidepressant-like effect in the FST. The
two-way ANOVA revealed a signiﬁcant effect of folic acid pretreat-
ment [F1,28=8.75, pb0.01], charybdotoxin treatment [F1,28=6.72,
Fig. 2. Effect of treatment of mice with glibenclamide (0.5 pg/site, i.c.v., panel A), char-
ybdotoxin (25 pg/site, i.c.v., panel B) or apamin (10 pg/site, i.c.v., panel C) combined
with a subeffective dose of folic acid (10 mg/kg, p.o.) in the open-ﬁeld test. Values
are expressed as mean+SEM (n=7).
Fig. 1. Effect of treatment of animals with glibenclamide (0.5 pg/site, i.c.v., panel A),
apamin (10 pg/site, i.c.v., panel B) or charybdotoxin (25 pg/site, i.c.v., panel C) in com-
bination with a subeffective dose of folic acid (10 mg/kg, p.o.) on the immobility time
in the FST. Values are expressed as mean+SEM (n=8). **pb0.01 compared with the
vehicle-treated group.
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ment [F1,28=5.94, pb0.05].
The post-hoc analyses revealed that the administration of the K+
channel blockers (glibenclamide, apamin or charybdotoxin), at
doses that do not produce an antidepressant-like effect in the FST,
produced a synergistic antidepressant-like effect when combined
with a subeffective dose of folic acid.
3.2. Effects of K+ channel blockers and folic acid in the open-ﬁeld test
The result depicted in Fig. 2A shows that the administration of
folic acid in combination with glibenclamide (0.5 pg/site, i.c.v.) did
not affect the animal locomotor activity in the open-ﬁeld test. The
two-way ANOVA revealed no differences for folic acid pretreatment
[F1,24=0.29, p=0.59], glibenclamide treatment [F1,24=0.01,
p=0.93] and pretreatment×treatment interaction [F1,24=1.90,
p=0.18]. The results of Fig. 2B indicated that combined treatment
with folic acid plus apamin (10 pg/site, i.c.v.) did not alter the loco-
motor proﬁle in the open-ﬁeld test. The two-way ANOVA revealed
no differences for folic acid pretreatment [F1,24=0.70, p=0.41], apa-
min treatment [F1,24=1.79, p=0.19] and pretreatment×treatment
interaction [F1,24=0.00, p=0.97]. Fig. 2C shows that the treatment
with folic acid combined to charybdotoxin (25 pg/site, i.c.v.) did not
induce alterations of locomotor activity in the open-ﬁeld test. Thetwo-way ANOVA revealed no differences for folic acid pretreatment
[F1,24=0.37, p=0.55], charybdotoxin treatment [F1,24=0.95,
p=0.34] and pretreatment×treatment interaction [F1,24=0.62,
p=0.44]. These results indicate that the reduction in the immobility
time observed in the FST when folic acid and K+ channel blockers
were administered in combination (Fig. 1A–C) was not due to a psy-
chostimulant effect.3.3. Effect of cromakalim on folic acid-induced anti-immobility effect in
the FST and in the number of crossings in the open-ﬁeld test
Fig. 3A shows that the pretreatment of mice with cromakalim (a
K+ channel opener, 10 μg/site, i.c.v.) was able to prevent the
antidepressant-like effect of folic acid (50 mg/kg, p.o.) in the FST.
The two-way ANOVA revealed signiﬁcant differences for folic acid
pretreatment [F1,24=19.48, pb0.01], cromakalim treatment
[F1,24=10.60, pb0.01] and pretreatment×treatment interaction
[F1,24=9.65, pb0.01].
Moreover, the results depicted in Fig. 3B shows the effect of cro-
makalim (10 μg/site, i.c.v.) combined with folic acid (50 mg/kg, p.o.)
in the open-ﬁeld test. This co-treatment did not produce any change
in the ambulatory behavior of mice, since the two-way ANOVA did
not reveal signiﬁcant differences for folic acid pretreatment
[F1,24=0.10, p=0.76], cromakalim treatment [F1,24=0.65, p=0.43]
and pretreatment×treatment interaction [F1,24=2.46, p=0.13].
Fig. 4. Schematic illustration for the different targets or pathways involved in the antidepressan
Folic acid can exert an antidepressant-like effect through the increase 5-HT and NA availabilit
PPARγ receptors and PI3K and/or AKT with the consequent inhibition of GSK3β activity (Budn
2008b, 2009), and inhibition of different types of K+ channels, as reported in the present study
charybdotoxin and apamin) combined of a subeffective dose of folic acid produced an antidep
acid. Based on literature data regarding the neuroprotective effects of folic acid, we propose that
2011; Figueiredo et al., 2011) are implicated in the molecular mechanisms involved in the anti
nucleus, locus coeruleus and amygdala cannot be ruled out.5-HT, serotonin; GSK3β, glycogen
methyl-D-aspartate receptor; NO, nitric oxide; PI3K, phosphoinositide 3-kinase; PPARγ, peroxi
Fig. 3. Effect of pretreatment of mice with cromakalim (10 μg/site, i.c.v.) on the anti-
immobility effect of folic acid (50 mg/kg, p.o.) in the FST (panel A) and open-ﬁeld test
(panel B). Values are expressed as mean+SEM (n=7). **pb0.01 compared with the ve-
hicle treated group; ##pb0.01 compared with the same group pretreated with vehicle.
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This study extends previous ﬁndings from our group that shows
that folic acid administration produces antidepressant-like effect in
the FST (Brocardo et al., 2008a, 2008b, 2009; Budni et al., 2011b).
Herein, we provide evidence that the antidepressant-like effect of
folic acid can be mediated by a block of different types of K+ chan-
nels, since subeffective doses of different types of K+ channel
blockers combined with a subeffective dose of folic acid produce an
antidepressant-like effect in the mouse FST. Additionally, to conﬁrm
our hypothesis, the pretreatment of mice with the K+ channel opener
cromakalim was able to prevent the antidepressant-like effect of folic
acid in the FST. Noteworthy, FST is a test widely used due to its pre-
dictive validity, since it is sensitive to all classes of antidepressant
drugs, including tricyclics, serotonin-speciﬁc reuptake inhibitors,
monoamine oxidase inhibitors, and atypicals (Petit-Demouliere
et al., 2005; Porsolt et al., 1977).
In this study, the open-ﬁeld test was used to exclude the possibility
that the synergistic effect of folic acid and K+ channel blockers in the
FST could be a consequence of an increased locomotor activity. Drugs
that induced hyperlocomotion may give a “false” positive effect in the
FST, whereas drugs decreasing locomotion may give a ‘false’ negative
result (Borsini and Meli, 1988; Rodrigues et al., 2005). Our results in-
dicate that the anti-immobility effect induced by folic acid in combina-
tion with K+ channel blockers in the FST is not due to a nonspeciﬁc
locomotor stimulant effect of the drugs combination, since drugs
alone or in combination did not signiﬁcantly alter locomotor activity.t-like effect of folic acid taking into account present results and previous literatureﬁndings.
y (Brocardo et al., 2008a), inhibition of NO synthesis (Brocardo et al., 2009), activation of
i et al., 2011b), inhibition of NMDAR and activation of the opioid system (Brocardo et al.,
. In this study, subeffective doses of different types of K+ channel blockers (glibenclamide,
ressant-like effect. Moreover, cromakalim prevented the antidepressant-like effect of folic
hippocampus and pre-frontal cortex (Brocardo et al., 2010; Budni et al., 2011a; Chen et al.,
depressant-like effect of folic acid, but the involvement of other brain regions, such as rafe
synthase kinase 3-beta; K+ channel, potassium channel; NA, noradrenaline; NMDAR, N-
some proliferator-activated receptor-gamma.
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levels in serum and erythrocytes of depressed patients and a thera-
peutical effect of this vitamin in combination with antidepressants
for treatment of refractory depression, two indicatives that folic acid
plays an important role in the pathophysiology of depression
(Coppen and Bailey, 2000; Coppen and Bolander-Gouaille, 2005). It
is important to mention that pre-clinical studies performed with
folic acid are not so abundant in the literature (Brocardo et al.,
2008a, 2008b, 2009; Budni et al., 2011b). Therefore, the mechanisms
underlying its antidepressant-like action deserve additional
investigations.
In this study several compounds were used as pharmacological
tools in the investigation of folic acid action mechanism in the FST:
glibenclamide, charybdotoxin and apamin. The combined treatment
with subeffective doses of these K+ channel blockers in combination
with folic acid provoked a robust reduction in immobility time, indic-
ative of an antidepressant-like behavioral proﬁle.
The K+ channel blockers glibenclamide, charybdotoxin and apa-
min act through different mechanisms, since they are known to selec-
tively block ATP-sensitive, large- and intermediate-conductance
calcium-activated and small-conductance calcium-activated K+ chan-
nels, respectively (Gehlert and Gackenheimer, 1993). Glibenclamide
blocks K+ channels frompancreaticβ-cell type, cardiac, smoothmuscle,
skeletal muscle, and some brain neurons (Clapp, 1995; Proks et al.,
2002). The ATP-regulated K+ channels are known as the target for sul-
fonylureas, as glibenclamide, oral hypoglycemic agent widely used in
the treatment of non-insulin-dependent diabetes mellitus to stimulate
insulin release from pancreatic islet β cells. The mechanism of stimula-
tion is through inhibition of ATP-regulated K+ channels (Edwards and
Weston, 1993; Ashcroft and Ashcroft, 1992). Charybdotoxin is a peptide
contained in the venom of the scorpion Leiurus quinquestriatus (Nelson
and Quayle, 1995) and it has been identiﬁed to cause potent selective
block of Ca2+-activated K+ channels present in GH3 anterior pituitary
cells and primary bovine aortic smooth muscle cells (Gimenez-Gallego
et al., 1988). Apamin is a peptide contained in the venom of the honey
bee Apis mellifera (Stocker, 2004). It selectivity blocks Ca2+-dependent
K+ conductance, since voltage-clamp techniques showed that apamin
has no effect on other ionic channels such as the fast Na+ channel, the
Et4N+-sensitive K+ channel, or the slow Ca2+ channel (Hugues et al.,
1982). These and other K+ channel blockers (3,4-diaminopyridine
[3,4-DAP] and gliquidone) were reported to exert an antidepressant-
like effect in the FST at higher doses than those employed in the present
study (Galeotti et al., 1999; Inan et al., 2004; Kaster et al., 2005).
Furthermore, ﬂuoxetine, desipramine, amitriptyline, nortriptyline,
clomipramine, maprotiline, citalopram and paroxetine, also produce
an inhibition of K+ currents, whichmight underlie their therapeutic ef-
fects (Choi et al., 2004; Kobayashi et al., 2004, 2006; Nicholson et al.,
2002; Tytgat et al., 1997; Yeung et al., 1999). Supporting the notion
that the K+ channels inhibition is related with the pathophysiology
and treatment of depression, the results by Takahashi et al. (2006) dem-
onstrated that continuous inhibition of wv GIRK2 channels (G protein-
activated inwardly rectifying K+ channels) by the antidepressants
ﬂuoxetine and desipramine caused a substantial suppression of the
neuronal cell death and resulted in improvement of motor abilities in
weaver mutant mice. Moreover, several studies have shown that the
combined administration of antidepressants and K+ channel blockers
produced an antidepressant-like effect in the FST in mice (Bortolatto
et al., 2010; Guo et al., 1995, 1996; Inan et al., 2004; Kaster et al.,
2007). Other compounds with antidepressant properties such as agma-
tine, adenosine and tramadol combined with several types of K+ chan-
nel blockers also produce an antidepressant-like effect in the FST (Budni
et al., 2007; Jesse et al., 2009; Kaster et al., 2007). Furthermore,
Heurteaux et al. (2006) demonstrated that the deletion of a gene coding
for TREK-1, a class of two-pore domain K+ channels, can cause resis-
tance to depression, increased 5-HT neurotransmission, and reduced
elevation of corticosterone levels under stress, suggesting thatalterations in the function and regulation of these channels may alter
mood. Therefore, these K+ channelsmay be a potential target for devel-
oping new antidepressants. Moreover, it was shown thatﬂuoxetine and
norﬂuoxetine are blockers of TREK-1K+ channels, consequently this
blocking effectmay occur in patients treatedwith these antidepressants
(Kennard et al., 2005). Accordingly, our results are in line with litera-
ture, since the combined treatment with a subeffective dose of folic
acid (a putative antidepressant agent) plus subeffective doses of K+
channel blockers produced an antidepressant-like effect in the FST in
mice.
Ca2+-activated and voltage-dependent K+ channel play a role in
the modulation of immobility time in the FST in mice (Inan et al.,
2004). In addition, large-conductance Ca2+-activated K+ channels
have been suggested as one of the physiological targets of NO in the
brain (Jeong et al., 2001). Moreover, blockers of different K+ channels
such as TEA, glibenclamide, apamin and charybdotoxin produced
antidepressant-like effect in FST and this effect was prevented by
the pretreatment of mice with L-arginine or sildenaﬁl. Thus, this re-
sults suggest that NO and cGMP are important modulators of some
K+ channels (Kaster et al., 2005). Considering that the K+ channels
represent one of the major downstream targets regulated by the acti-
vation of NMDA receptors and L-arginine–NO pathway, it is believed
that the inhibition of K+ channels may be a consequence of inhibition
of NMDA receptors and of NO production induced by folic acid, since a
previous report indicates that the antidepressant-like effect of this vi-
tamin may be mediated by, inhibition of NMDA receptors and NO
synthesis (Brocardo et al., 2008b). Hence, an indirect modulation of
the K+ channels by folic acid via NMDA–L-arginine–NO pathway
could account for the behavioral results reported in the present
study. However, the possibility that folic acid causes a direct inhibi-
tion of these channels cannot be ruled out.
To further reinforce our hypothesis, we also show that the pre-
treatment of mice with a K+ channel opener, cromakalim, prevented
the decrease in the immobility time induced by an effective dose of
folic acid in the FST, without changing the ambulatory behavior in
the open-ﬁeld test. Cromakalim is a K+ channel opener that has
high sensitivity to KATP channels (Clapp, 1995). Literature data report
that the administration of cromakalim at higher doses than the one
used in the present study increases the immobility time in the FST
(Galeotti et al., 1999). In addition, Redrobe et al. (1996) demonstrat-
ed that the pretreatment of animals with cromakalim was able to re-
verse the anti-immobility effect of antidepressants such as
imipramine, amitriptyline, desipramine and paroxetine.
Noteworthy, Kaster et al. (2007) showed that a subeffective dose
of ﬂuoxetine combined with subeffective doses of K+ channel
blockers produced an antidepressant-like effect in the FST and this ef-
fect was prevented by K+ channel openers. These results are compa-
rable with the results found in the present study with folic acid,
which may likely exert antidepressant-like effect in the FST by a
mechanism similar to either ﬂuoxetine or K+ channel blockers.
The most common cause for adverse cardiac events by antide-
pressants (mainly tricyclic antidepressants) is acquired long QT syn-
drome, which produces electrocardiographic abnormalities that
have been associated with syncope, torsade de pointes arrhythmias,
and sudden cardiac death. Acquired long QT syndrome is often
caused by direct block of the cardiac potassium current I(Kr)/hERG,
which is crucial for terminal repolarization in human heart (Dennis
et al., 2011). In contrast to tricyclic antidepressants that are reported
to cause adverse cardiac effects, folic acid has beneﬁcial effects or no
harm on the risk of cardiovascular diseases (Czeizel, 1996; Bazzano
et al., 2006). In addition, a recent study showed that folic acid has
protective properties against homocysteine-induced oxidative–
nitrative stress in the heart of rats (Kolling et al., 2011). Therefore,
it is feasible to suppose that folic acid does not signiﬁcantly block
cardiac K+ channels implicated with cardiovascular risks and that
the association of this vitamin with K+ channel blockers such as
153J. Budni et al. / Pharmacology, Biochemistry and Behavior 101 (2012) 148–154glibenclamide and/or antidepressants for the treatment of depres-
sion might be a therapeutic strategy for preventing or reducing car-
diovascular risks associated with the blockade of cardiac K+
channels. However, further studies regarding this issue are
necessary.
5. Conclusions
The results of this study indicate that subeffective doses of differ-
ent types of K+ channel blockers (glibenclamide, charybdotoxin and
apamin) combined of a subeffective dose of folic acid produce an
antidepressant-like effect in the mouse FST. Moreover, cromakalim
was able to reverse the antidepressant-like effect produced by a
higher dose of folic acid. Altogether, the results shown herein suggest
that the antidepressant-like effect of folic acid in the FST in mice may
involve the modulation of neuronal excitability via inhibition of K+
channels (Fig. 4).
Conﬂict of interest
The Authors declare that there is no conﬂict of interest.
Acknowledgments
This study was supported by the FINEP research grant “Rede
Instituto Brasileiro de Neurociência (IBN-Net)” # 01.06.0842-00,
CAPES and CNPq (Brazil).
References
Abou-Saleh MT, Coppen A. Folic acid and the treatment of depression. J Psychosom Res
2006;61:285–7.
Alpert JE, Mischoulon D, Rubenstein GE, Bottonari K, Nierenberg AA, Fava M. Folinic
acid (Leucovorin) as an adjunctive treatment for SSRI-refractory depression. Ann
Clin Psychiatry 2002;14:33–8.
Ashcroft SJ, Ashcroft FM. The sulfonylurea receptor. Biochim Biophys Acta
1992;1175(1):45–9.
Bazzano LA, Reynolds K, Holder KN, He J. Effect of folic acid supplementation on risk of
cardiovascular diseases: a meta-analysis of randomized controlled trials. JAMA
2006;296(22):2720–6.
Borsini F, Meli A. Is the forced swimming test a suitable model for revealing antidepres-
sant activity? Psychopharmacology (Berl) 1988;94(2):147–60.
Bortolatto CF, Jesse CR, Wilhelm EA, Nogueira CW. Involvement of potassium channels
in the antidepressant-like effect of venlafaxine in mice. Life Sci 2010;86(9–10):
372–6.
Brocardo PS, Budni J, Kaster MP, Santos ARS, Rodrigues ALS. Folic acid administration
produces an antidepressant-like effect in mice: evidence for the involvement of
the serotonergic and noradrenergic systems. Neuropharmacology 2008a;54:
464–73.
Brocardo PS, Budni J, Lobato KR, Kaster MP, Rodrigues ALS. Antidepressant-like effect
of folic acid: Involvement of NMDA receptors and L-arginine-nitric oxide-cyclic
guanosine monophosphate pathway. Eur J Pharmacol 2008b;598:37–42.
Brocardo PS, Budni J, Lobato KR, Santos ARS, Rodrigues ALS. Evidence for the involve-
ment of the opioid system in the antidepressant-like effect of folic acid in the
mouse forced swimming test. Behav Brain Res 2009;200:122–7.
Brocardo PS, Budni J, Pavesi E, Franco JL, Uliano-Silva M, Trevisan R, et al. Folic acid ad-
ministration prevents ouabain-induced hyperlocomotion and alterations in oxida-
tive stress markers in the rat brain. Bipolar Disord 2010;12(4):414–24.
Budni J, Gadotti VM, Kaster MP, Santos AR, Rodrigues ALS. Role of different types of
potassium channels in the antidepressant-like effect of agmatine in the mouse
forced swimming test. Eur J Pharmacol 2007;575:87–93.
Budni J, Romero A, Molz S, Martín-de-Saavedra MD, Egea J, Del Barrio L, et al. Neurotox-
icity induced by dexamethasone in the human neuroblastoma SH-SY5Y cell line
can be prevented by folic acid. Neuroscience 2011a;190:346–53.
Budni J, Lobato KR, Binfaré RW, Freitas AE, Costa AP, SaavedraMDM, et al. Involvement of
PI3K, GSK-3β and PPARγ in the antidepressant-like effect of folic acid in the forced
swimming test in mice. J Psychopharmacol 2011b. doi:10.1177/0269881111424456.
Chen TF, Chiu MJ, Huang CT, Tang MC, Wang SJ, Wang CC, et al. Changes in dietary
folate intake differentially affect oxidised lipid and mitochondrial DNA damage in
various brain regions of rats in the absence/presence of intracerebroventricularly
injected amyloid β-peptide challenge. Br J Nutr 2011;105(9):1294–302.
Choi JS, Choi BH, Ahn HS, Kim MJ, Han TH, Rhie DJ. Fluoxetine inhibits A-type potassium
currents in primary cultured rat hippocampal neurons. Brain Res 2004;1018:201–7.
Clapp LH. Regulation of glibenclamide-sensitive K+ current by nucleotide phosphates
in isolated rabbit pulmonary myocytes. Cardiovasc Res 1995;3:460–8.Coppen A, Bailey J. Enhancement of the antidepressant action of ﬂuoxetine by folic
acid: a randomised, placebo controlled trial. J Affect Disord 2000;60:121–30.
Coppen A, Bolander-Gouaille C. Treatment of depression: time to consider folic acid
and vitamin B12. J Psychopharmacol 2005;19:59–65.
Czeizel AE. Reduction of urinary tract and cardiovascular defects by periconceptional
multivitamin supplementation. Am J Med Genet 1996;62(2):179–83.
Dennis AT, Nassal D, Deschenes I, Thomas D, Ficker E. Antidepressant-induced ubiqui-
tination and degradation of the cardiac potassium channel hERG. J Biol Chem
2011;286(39):34413–25.
Edwards G, Weston AH. Induction of a glibenclamide-sensitive K-current by modiﬁca-
tion of a delayed rectiﬁer channel in rat portal vein in insulinoma cells. Br J Phar-
macol 1993;110(4):1280–1.
Fava M, Mischoulon D. Folate in depression: efﬁcacy, safety, differences in formula-
tions, and clinical issues. J Clin Psychiatry 2009;70(5):12–7.
Fenech M. Folate, DNA damage and the aging brain. Mech Ageing Dev 2010;131(4):
236–41.
Figueiredo CP, Bicca MA, Latini A, Prediger RD, Medeiros R, Calixto JB. Folic acid plus α-
tocopherol mitigates amyloid-β-induced neurotoxicity through modulation of
mitochondrial complexes activity. J Alzheimers Dis 2011;24(1):61–75.
Galeotti N, Ghelardini C, Caldari B, Bartolini A. Effect of potassium channel modulators
in mouse forced swimming test. Br J Pharmacol 1999;126:1653–9.
Gehlert DR, Gackenheimer SL. Comparison of the distribution of binding sites for the
potassium channel ligands [125I]apamin, [125I]charybdotoxin and [125I]iodogly-
buride in the rat brain. Neuroscience 1993;52(1):191–205.
Gimenez-Gallego G, Navia MA, Reuben JP, Katz GM, Kaczorowski GJ, Garcia ML. Puriﬁ-
cation, sequence, and model structure of charybdotoxin, a potent selective inhibi-
tor of calcium-activated potassium channels. Proc Natl Acad Sci U S A 1988;85(10):
3329–33.
Godfrey PS, Toone BK, CarneyMW, Flynn TG, Bottiglieri T, LaundyM, et al. Enhancement of
recovery from psychiatric illness by methylfolate. Lancet 1990;336(8712):392–5.
Guo WY, Todd KG, Bourin M, Hascoet M. The additive effects of quinine on antidepres-
sant drugs in the forced swimming test in mice. Psychopharmacology 1995;121:
173–9.
Guo W, Todd K, Bourin M, Hascoet M, Kouadio F. Additive effects of glyburide and
antidepressants in the forced swimming test: evidence for the involvement of
potassium channel blockade. Pharmacol Biochem Behav 1996;54:725–30.
Heurteaux C, Lucas G, Guy N, El Yacoubi M, Thummler S, Peng XD, et al. Deletion of the
background potassium channel TREK-1 results in a depression-resistant pheno-
type. Nat Neurosci 2006;9:1134–41.
Hugues M, Romey G, Duval D, Vincent JP, Lazdunski M. Apamin as a selective blocker of
the calcium-dependent potassium channel in neuroblastoma cells: voltage-clamp
and biochemical characterization of the toxin receptor. Proc Natl Acad Sci U S A
1982;79(4):1308–12.
Inan SY, Yalcin I, Aksu F. Dual effects of nitric oxide in the mouse forced swimming test:
possible contribution of nitric oxide-mediated serotonin release and potassium
channel modulation. Pharmacol Biochem Behav 2004;77:457–64.
Jeong SY, Ha TS, Park CS, Uhm DY, Chung S. Nitric oxide directly activates large conduc-
tance Ca2+-activated K+ channels (rSlo). Mol Cells 2001;12:97-102.
Jesse CR, Wilhelm EA, Barbosa NB, Nogueira CW. Involvement of different types of
potassium channels in the antidepressant-like effect of tramadol in the mouse
forced swimming test. Eur J Pharmacol 2009;613(1–3):74–8.
Kaster MP, Ferreira PK, Santos ARS, Rodrigues ALS. Effects of potassium channel inhib-
itors in the forced swimming test: possible involvement of L-arginine-nitric oxide-
soluble guanylate cyclase pathway. Behav Brain Res 2005;165:204–9.
Kaster MP, Budni J, Binfare RW, Santos ARS, Rodrigues ALS. The inhibition of different
types of potassium channels underlies the antidepressant-like effect of adenosine
in the mouse forced swimming test. Prog Neuropsychopharmacol Biol Psychiatry
2007;31:690–6.
Kennard LE, Chumbley JR, Ranatunga KM, Armstrong SJ, Veale EL, Mathie A. Inhibition
of the human two-pore domain potassium channel, TREK-1, by ﬂuoxetine and its
metabolite norﬂuoxetine. Br J Pharmacol 2005;144(6):821–9.
Kobayashi T, Washiyama K, Ikeda K. Inhibition of G protein-activated inwardly rectifying
K+ channels by various antidepressant drugs. Neuropsychopharmacology 2004;29:
1841–51.
Kobayashi T, Washiyama K, Ikeda K. Inhibition of G protein-activated inwardly rectifying
K+ channels by the antidepressant paroxetine. J Pharmacol Sci 2006;102:278–87.
Kolling J, Scherer EB, da Cunha AA, da Cunha MJ, Wyse AT. Homocysteine induces
oxidative–nitrative stress in heart of rats: prevention by folic acid. Cardiovasc
Toxicol 2011;11(1):67–73.
Kronenberg G, Colla M, Endres M. Folic acid, neurodegenerative and neuropsychiatric
disease. Curr Mol Med 2009;9:315–23.
Lee S, Jeong J, Kwak Y, Park SK. Depression research: where are we now? Mol Brain
2010;3:8.
Morris DW, Trivedi MH, Rush AJ. Folate and unipolar depression. J Altern Complement
Med 2008;14(3):277–85.
Nelson MT, Quayle JM. Physiological roles and properties of potassium channels in
arterial smooth muscle. Am J Physiol 1995;268:799–822.
Nicholson GM, Blanche T, Mansﬁeld K, Tran Y. Differential blockade of neuronal
voltage-gated Na+ and K+ channels by antidepressant drugs. Eur J Pharmacol
2002;452:35–48.
Petit-Demouliere B, Chenu F, Bourin M. Forced swimming test in mice: a review of
antidepressant activity. Psychopharmacology (Berl) 2005;177(3):245–55.
Porsolt RD, Bertin A, Jalfre M. Behavioral despair in mice: a primary screening test for
antidepressants. Arch Int Pharmacodyn Ther 1977;229:327–36.
Proks P, Reimann F, Green N, Gribble F, Ashcroft F. Sulfonylurea stimulation of insulin
secretion. Diabetes 2002;51(3):S368–76.
154 J. Budni et al. / Pharmacology, Biochemistry and Behavior 101 (2012) 148–154Redrobe JP, Pinot P, Bourin M. The effect of the potassium channel activator, cromakalim,
on antidepressant drugs in the forced swimming test inmice. FundamClin Pharmacol
1996;10:524–8.
Rodrigues ALS, Rocha JBT, Mello CF, Souza DO. Effect of perinatal lead exposure on rat
behavior in open-ﬁeld and two-way avoidance tasks. Pharmacol Toxicol 1996;79:
150–6.
Rodrigues ALS, Rosa JM, Gadotti VM, Goulart EC, Santos MM, Silva AV, et al. Santos ARS
Antidepressant-like and antinociceptive-like actions of 4-(4′-chlorophenyl)-6-(4″-
methylphenyl)-2-hydrazinepyrimidine Mannich base in mice. Pharmacol Biochem
Behav 2005;82:156–62.
Sarris J, Schoendorfer N, KavanaghDJ. Major depressive disorder and nutritional medicine:
a review of monotherapies and adjuvant treatments. Nutr Rev 2009;67:125–31.Shin JH, Chung S, Park EJ, Uhm DY, Suh CK. Nitric oxide directly activates calcium-
activated potassium channels from rat brain reconstituted into planar lipid bilayer.
FEBS Lett 1997;415:299–302.
Stocker M. Ca2+-activated K+ channels: molecular determinants and function of the
SK family. Nat Rev Neurosci 2004;5:758–70.
Takahashi T, Kobayashi T, Ozaki M, Takamatsu Y, Ogai Y, Ohta M, et al. G protein-
activated inwardly rectifying K+ channel inhibition and rescue of weaver mouse
motor functions by antidepressants. Neurosci Res 2006;54:104–11.
Tytgat J, Maertens C, Daenens P. Effect of ﬂuoxetine on a neuronal, voltage-dependent
potassium channel (Kv1.1). Br J Pharmacol 1997;122:1417–24.
Yeung SY, Millar JA, Mathie A. Inhibition of neuronal KV potassium currents by the
antidepressant drug, ﬂuoxetine. Br J Pharmacol 1999;128:1609–15.
